Anti-Trastuzumab Polyclonal Antibody

Catalog No.

PAC09601

Host species

Rabbit

Isotype

IgG

Clonality

Polyclonal

Immunogen

Trastuzumab

Tested applications

ELISA: 1:4000-1:8000

Target

Rabbit polyclonal to Herceptin.

Specificity

The product is specific for Trastuzumab. This antibody serves as an excellent positive control for Trastuzumab immunogenicity (ADA) assays.

Concentration

0.4 mg/ml

Purification

Purified by antigen affinity column.

Accession

CAS: 180288-69-1

Applications

ELISA

Form

Liquid

Storage buffer

0.01M PBS, pH 7.4, 50% Glycerol, 0.05% Proclin 300.

Stability and Storage

The product can be stored for 2 - 3 weeks at 2 to 8°C or for up to 12 months at -20°C. Avoid repeated freezing and thawing cycles.

Background

Trastuzumab with the brand name Herceptin, is an FDA-approved drug for HER2-targeted therapy for breast cancer. It is a recombinant humanized monoclonal antibody (IgG1 kappa). Trastuzumab binds to HER2 receptor present on the surface of HER2-positive tumour cells and suppresses the cells growth and proliferation.

ctDNA Analysis in ERBB2-Amplified Colorectal Cancer: Biomarker Analysis of the MyPathway Trial., PMID:40512191

Advancing Antibody-Drug Conjugates: Precision Oncology Approaches for Breast and Pancreatic Cancers., PMID:40507272

Preirradiation of Spheroids with 225Ac-Trastuzumab Improves Penetration of 225Ac-Liposomes and MIRDcell Predictions of Responses to Drug Cocktails., PMID:40506236

Comparative pharmacological analysis of fam-trastuzumab deruxtecan-nxki and sacituzumab govitecan-hziy: Two recently developed chemotherapies in the crucial battle against breast cancer., PMID:40502326

Effects of concurrent HER2-directed therapy on development of cerebral radionecrosis after stereotactic radiotherapy: a systematic review., PMID:40493045

Novel Quaternary Ammonium Salt-Linked STING Agonist Antibody-Drug Conjugate: Synergistic Activation of Tumor Immunity with Mitigated Off-Target Toxicity., PMID:40492586

Reinforced Polymer-Nanoparticle Hydrogels for Subcutaneous and Sustained Delivery of Trastuzumab., PMID:40489148

Treatment of breast cancer in a patient with sickle cell disease., PMID:40484435

Advancing Neoadjuvant Therapy with Inetetamab for HER2-Positive Breast Cancer., PMID:40482910

Spatial discovery of pyrotinib overcoming HER2-positive breast cancer resistance by breaking fibroblast-induced immune barriers., PMID:40480079

Site-Specific Immune and Stromal Architecture Drive Resistance to Trastuzumab Deruxtecan in HER2+ Metastatic Breast Cancer., PMID:40475468

Design, Synthesis, and Biological Evaluation of Evodiamine Derivatives as Antibody-Drug Conjugate (ADC) Payloads., PMID:40474320

225Ac α-Pretargeted Radioimmunotherapy of Human Epidermal Growth Factor Receptor 2-Expressing Breast Cancer., PMID:40473462

Advances and Future Perspectives of HER2 Mutations in Non-Small Lung Cancer (NSCLC), Especially in China., PMID:40472040

Trastuzumab-deruxtecan shows interesting disease control in a multitreated patient with ERBB2 amplified parotid carcinoma, a case report., PMID:40470107

TCHL - a phase II neo-adjuvant study assessing TCH (docetaxel, carboplatin and trastuzumab) and TCHL (docetaxel, carboplatin, trastuzumab and lapatinib) in HER-2 positive breast cancer patients: a 5-year follow-up with serum biomarker analysis., PMID:40468999

Successful Treatment of HER2 V659E Mutation-Positive Lung Adenocarcinoma With Trastuzumab Deruxtecan: A Case Report., PMID:40468744

Improving the Therapeutic Selectivity of Trastuzumab Deruxtecan Using 8C2 Fab Fragments., PMID:40467988

Adverse effect of trastuzumab deruxtecan in solid tumours: a systematic review and meta-analysis., PMID:40466817

Targeting SLC7A11-mediated cysteine metabolism for the treatment of trastuzumab-resistant HER2-positive breast cancer., PMID:40464376

Mechanisms of resistance to antibody-drug conjugates in cancers., PMID:40460510

New Treatment Approaches for Triple-Negative Breast Cancer., PMID:40460322

The Rapidly Evolving Landscape of Human Epidermal Growth Factor Receptor 2 (HER2) Testing in Endometrial Carcinoma and Other Gynecologic Malignancies., PMID:40452624

Radionuclide-Aided Improvement of the Therapeutic Efficacy of Novel Antibody-Drug Conjugates against HER2-Expressing Cancers., PMID:40448644

Radiobioconjugate of Kadcyla with Radioactive Gold Nanoparticles for Targeted Therapy of HER2-Overexpressing Cancers., PMID:40443068

[Leptomeningeal disease in breast cancer: State of the art and future directions]., PMID:40441935

Patient-reported outcomes with trastuzumab deruxtecan in hormone receptor-positive, HER2-low or HER2-ultralow metastatic breast cancer: results from the randomized DESTINY-Breast06 trial., PMID:40441802

Sequential Antibody-Drug Conjugate Therapy in Patients With Metastatic Breast Cancer Treated With Sacituzumab Govitecan and Trastuzumab Deruxtecan., PMID:40440568

Molecular imaging predicts trastuzumab-deruxtecan (T-DXd) response in head and neck cancer xenograft models., PMID:40437743

Real-world data on trastuzumab emtansine (TDM1) efficacy and safety: Results of a single-centre retrospective study of HER2-positive metastatic breast cancer patients., PMID:40437155

Pyrotinib promotes the antitumor effect of T-DM1 by increasing drug endocytosis in HER2-positive breast cancer., PMID:40437017

Efficacy and Safety of Antibody-Drug Conjugates for Lung Cancer Therapy: A Systematic Review of Randomized and Non-Randomized Clinical Trials., PMID:40430899

Impact of HER2 Status Assessed by Immunohistochemistry on Treatment Response in Patients with Metastatic Breast Cancer Receiving Trastuzumab Emtansine., PMID:40428777

Integrating Biochemical and Computational Approaches Reveal Structural Insights in Trastuzumab scFv-Fc Antibody Engineering., PMID:40427499

Cardio-Renal and Systemic Effects of SGLT2i Dapagliflozin on Short-Term Anthracycline and HER-2-Blocking Agent Therapy-Induced Cardiotoxicity., PMID:40427493

Hedgehog inhibitors exert anti-proliferation effects and synergistically interact with trastuzumab in HER2-positive gastric cancer models., PMID:40426308

Investigation of dose-exposure-response relationship for adeno-associated virus-mediated delivery of antibody genes., PMID:40424661

Balancing Reactivity and Specificity: Fc-Binding O-Acyl Hydroxamate Reagents for Site-Selective Antibody Labeling at Lys248., PMID:40423997

Advances in Targeted Therapy for Brain Metastases in Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer: A Focus on ADCs and TKIs., PMID:40416059

Clinical benefit of continuation of PD-1 inhibitors after progression on first-line chemoimmunotherapy in metastatic gastric cancer and biomarker exploration., PMID:40413463

Efficacy and safety of trastuzumab deruxtecan in HER2-positive breast cancer patients with brain metastases after failure of pyrotinib-based therapy., PMID:40404737

T-DM1 with concurrent radiotherapy in HER2-positive breast cancer: preclinical evaluation and mechanisms, prediction, and exploration of adverse effects., PMID:40402389

Cost and Cost-Effectiveness of Treating Human Epidermal Growth Factor Receptor 2-Low Metastatic Breast Cancer., PMID:40397834

TRA/MEL immunoliposomes act as a targeted medicine in BT-474 breast cancer cells., PMID:40396920

Clinical application of trastuzumab and docetaxel in the chemotherapy of human epidermal growth factor receptor 2 positive breast cancer patients., PMID:40391840

A Reflection on the Evolution of Antibody-Based Therapies in Oncology: Trastuzumab as an Exemplar-Commentary on Dijkers et al., PMID:40388070

Update Breast Cancer 2024 Part 3 - Patients with Advanced Stage Breast Cancer., PMID:40386501

A platform for SpyCatcher conjugation to native antibodies., PMID:40386161

Validation and Prospective Testing of a High Sensitivity, Quantitative Analytic Assay for HER2 on Histopathology Slides., PMID:40385428

Trastuzumab deruxtecan versus trastuzumab emtansine for human epidermal growth factor receptor 2 positive metastatic breast cancer: cost-effectiveness analysis from Iranian experience., PMID:40380283

Document Download

Anti-Trastuzumab Polyclonal Antibody.pdf